Showing 2151-2160 of 8839 results for "".
First, Do No Harm
https://practicaldermatology.com/conferences/scale-2023/first-do-no-harm/20206/Joel L. Cohen, MD, and Mathew M. Avram, MD, JD, discuss why dermatologists should report any side effects to the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database.Lidocaine Shortage Update
https://practicaldermatology.com/conferences/scale-2023/lidocaine-shortage-update/20196/The current lidocaine and lidocaine with epinephrine shortage is affecting practices across the country. Joel L. Cohen, MD, and George Hruza, MD, weigh in on the shortage and potential solutions and how to minimize toxicity risks when mixing and matching different anesthetics.How Incyte Is Following the Science to Develop Innovative Solutions for Immune-Mediated Skin Conditions
https://practicaldermatology.com/topics/atopic-dermatitis/how-incyte-is-following-the-science-to-develop-innovative-solutions-for-immune-mediated-skin-conditions/20158/Jim Lee, head of the Inflammation and Autoimmunity clinical development group at Incyte, discusses the role of the immune system in atopic dermatitis (AD) and vitiligo and shares how Incyte is following the science to develop innovative options impacting the lives of people with these conditions.Tolerability of JAK Inhibitors Used in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/tolerability-of-jak-inhibitors-used-in-dermatology/20126/Although safety and tolerability are often intertwined, they are distinct considerations. Topical and oral JAKs used in dermatology today seem to offer good tolerability. Adelaide A. Hebert, MD and Matthew Zirwas, MD discuss potential side effects, management, and monitoring in pediatric and adult pDermWireTV: Doximity Physician Compensation Report, EADV Updates, PsO in the Know
https://practicaldermatology.com/topics/psoriasis/dermwiretv-doximity-physician-compensation-report-eadv-updates-pso-in-the-know/19870/Doximity’s fourth annual Physician Compensation Report shows a widening of the gender pay gap. From biologics and investigational molecules for psoriasis to socks to prevent foot odors, the European Academy of Dermatology and Venereology annual meeting highlights emerging therapies for dermatology pDermWireTV: Clinical Support Tech Data; Dupixent, Stelara Updates; Rihanna Launches Fenty Skin
https://practicaldermatology.com/topics/psoriasis/dermwiretv-clinical-support-tech-data-dupixent-stelara-updates-rihanna-launches-fenty-skin/19835/A feasibility study in collaboration between LEO Innovation Lab, VisualDX, and the German Association of Dermatological Prevention supports technology to assist in diagnosis of skin conditions. Leo Pharma’s investigational JAK inhibitor delgocitinib cream is Fast Tracked by the FDA for the potentiaCrisis Management: Office Operations, Part 1
https://practicaldermatology.com/topics/practice-management/crisis-management-office-operations-part-1/18181/How are primarily cosmetic dermatology practices dealing with shutdowns and preparing for the future? Host Neal Bhatia, MD discusses with Deirdre Hooper, MD, Ashish Bhatia, MD, Kevin Pinski, MD, and Nancy Samolitis, MD.Noah Worcester 2024: Dr. Bridges on Practice Management
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-bridges-practice-management/24580/Alina Bridges, DO, FAAD, summarizes her lecture on practice management and coding at the 2024 Noah Worcester Dermatological Society meeting.Clinical Conversations: Risks vs Benefits of JAK Inhibitors
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-risks-vs-benefits-of-jak-inhibitors/20108/Clinical data for JAK inhibitors show clear benefits for many patients. But these drugs are associated with certain risks and class warnings. Matt Zirwas, MD and Adelaide Hebert, MD describe how they weigh risks, educate patients, and optimize long-term management.Scientifically Speaking: Sunscreen Update from Terri Michele, MD of the FDA CDER
https://practicaldermatology.com/topics/skin-cancer-photoprotection/scientifically-speaking-sunscreen-update-from-terri-michele-md-of-the-fda-cder/19853/What is the latest on sunscreen labeling? What are implications of recent serology studies? And could new screening agents come to the US market? Host Joel L. Cohen, MD talks to Terri Michele, MD, Director of the Office of Nonprescription Drugs in FDA CDER about these and other hot topics in sun pro